Suppr超能文献

肝脂肪酶突变可能降低CETP水平高的血液透析患者的血管疾病患病率。

Hepatic lipase mutation may reduce vascular disease prevalence in hemodialysis patients with high CETP levels.

作者信息

Kimura Hideki, Miyazaki Ryoichi, Imura Toshio, Masunaga Shinya, Suzuki Satoru, Gejyo Fumitake, Yoshida Haruyoshi

机构信息

Department of Clinical Laboratory Medicine and Nephrology, Faculty of Medicine, Fukui Medical University, Fukui, Japan.

出版信息

Kidney Int. 2003 Nov;64(5):1829-37. doi: 10.1046/j.1523-1755.2003.00285.x.

Abstract

BACKGROUND

Uremic dyslipidemia characterized by reduced high-density lipoprotein (HDL) cholesterol levels is one of the major contributors to the high incidence of cardiovascular disease in hemodialysis patients. Hepatic lipase (HL), together with cholesteryl ester transfer protein (CETP), may not only promote reverse cholesterol transport but also enhance production of small, dense, more atherogenic low-density lipoprotein (LDL). A common C-514T mutation of the promoter region of the HL gene reportedly increases HDL cholesterol levels. However, whether the HL mutation is antiatherogenic or proatherogenic has remained unknown in uremic patients and the general population.

METHODS

We investigated the influence of the mutation and its interaction with CETP on HDL cholesterol levels and the apparent atherosclerotic complications in 183 hemodialysis patients aged over 30 years who had received no antilipemic drugs.

RESULTS

In patients with CETP levels > or =2.2 microg/mL [high CETP (HCT) group, N = 97], subjects with the TT genotype had a significantly higher level of HDL cholesterol than those without TT genotype (56.8 +/- 15.9 mg/dL vs. 45.7 +/- 13.4 mg/dL, P < 0.001), but not in patients with CETP levels <2.2 microg/mL [low CETP (LCT) group]. Multiple linear regression analysis showed that the TT genotype was a major independent positive determinant for HDL cholesterol levels in the HCT not LCT group. Among the HCT group patients, subjects with the TT genotype (N = 25) had a tendency toward lower prevalence of vascular disease than those without TT genotype (N = 72) (4.0% vs. 22.2%, P < 0.07). In this subgroup, TT genotype had an independent odds ratio of 0.041 (95% CI 0.002 to 0.75, P < 0.05) after adjusting for other risk factors.

CONCLUSION

The TT genotype of HL mutation may serve as a protective factor against vascular disease by increasing HDL cholesterol levels in hemodialysis patients with higher CETP levels.

摘要

背景

以高密度脂蛋白(HDL)胆固醇水平降低为特征的尿毒症血脂异常是血液透析患者心血管疾病高发病率的主要促成因素之一。肝脂酶(HL)与胆固醇酯转运蛋白(CETP)不仅可能促进胆固醇逆向转运,还可能增强小而密的、更具动脉粥样硬化性的低密度脂蛋白(LDL)的生成。据报道,HL基因启动子区域常见的C-514T突变可提高HDL胆固醇水平。然而,在尿毒症患者和普通人群中,HL突变是抗动脉粥样硬化还是促动脉粥样硬化仍不清楚。

方法

我们调查了该突变及其与CETP的相互作用对183例年龄超过30岁且未接受过降脂药物治疗的血液透析患者HDL胆固醇水平及明显动脉粥样硬化并发症的影响。

结果

在CETP水平≥2.2μg/mL的患者中[高CETP(HCT)组,N = 97],TT基因型的受试者HDL胆固醇水平显著高于无TT基因型的受试者(56.8±15.9mg/dL对45.7±13.4mg/dL,P < 0.001),但在CETP水平<2.2μg/mL的患者中[低CETP(LCT)组]并非如此。多元线性回归分析显示,TT基因型是HCT而非LCT组HDL胆固醇水平的主要独立正向决定因素。在HCT组患者中,TT基因型的受试者(N = 25)血管疾病患病率有低于无TT基因型受试者(N = 72)的趋势(4.0%对22.2%,P < 0.07)。在该亚组中,调整其他危险因素后,TT基因型的独立比值比为0.041(95%CI 0.002至0.75,P < 0.05)。

结论

HL突变的TT基因型可能通过提高CETP水平较高的血液透析患者的HDL胆固醇水平,作为预防血管疾病的保护因素。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验